TGTX Q2 2024 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73M+357.0% YoY

Gross Profit

$65M88.7% margin

Operating Income

$9M12.0% margin

Net Income

$7M9.4% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+15.7%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$6M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$401M

Total Liabilities

$224M

Stockholders' Equity

$178M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$16M	+357.0%
Gross Profit	$65M	$14M	+360.1%
Operating Income	$9M	-$45M	+119.7%
Net Income	$7M	-$48M	+114.4%

Revenue Segments

Product

$73M99%

Other Revenue

$682,0001%

Royalty

$150,0000%

License Revenue

$38,0000%